Clinuvel Pharmaceuticals Limited has announced that analyses of its Phase III US study (CUV039) evaluating the administration of SCENESSE® (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) had shown a clinically meaningful treatment effect. The drug was well tolerated with no safety concerns identified.